

A multi-centre study of neurofilament assay reliability and inter-laboratory variability.

Gray E¹, Oeckl P², Amador MDM⁴, Andreasson U³, An J¹⁰, Blennow K³, Bowser R¹⁰, De Schaepdryver M⁷, Heslegrave A⁹, Kuhle J⁵, Koel-Simmelink M⁸, Lamari F⁴, Lombardi V⁶, Malaspina A⁶, Nilsson I³, Poesen K⁷, Salachas F⁴, Steinacker P², Teunissen C⁸, Zetterberg H^{3,9,10}, Ludolph A², Jeromin A¹¹, Turner MR¹, Otto M²

¹Nuffield Department of Clinical Neuroscience, University of Oxford; ²University of Ulm, Ulm, Germany; ³University of Gothenburg, Gothenburg, Sweden; ⁴Salpêtrière Hospital, Paris, France; ⁵University of Basel, Basel, Switzerland; ⁶Queen Mary University of London, London, United Kingdom; ⁷University of Leuven, Leuven, Belgium; ⁸VU Medical Centre, Amsterdam, Netherlands; ⁹University College London, Institute of Neurology, London, United Kingdom; ¹⁰UK Dementia Research Institute at UCL, London, United Kingdom; ¹¹Iron Horse Diagnostics, Inc., Scottsdale, AZ, USA

Correspondence:	Professor Markus Otto	Professor Martin Turner
	University of Ulm	West Wing Level 6
	Germany	John Radcliffe Hospital
		Oxford, OX3 9DU, UK

Keywords

Amyotrophic lateral sclerosis; neurofilament; biomarker

Word counts

Main (excluding abstract, figure legends, tables and table legends):

Abstract 208; Main 1162; Figures 3; Tables 3; References 14

Keywords: amyotrophic lateral sclerosis, motor neuron disease, neurofilaments, assay, round robin

Abstract

Objectives: Significantly elevated levels of neurofilament light chain (NfL) and phosphorylated neurofilament heavy chain (pNfH) have been described in the blood and cerebrospinal fluid (CSF) of amyotrophic lateral sclerosis (ALS) patients. The aim of this study was to evaluate the analytical performance of different neurofilament assays in a round robin with 10 centers across Europe/U.S.

Methods: Serum, plasma and CSF samples from a group of five ALS and five neurological control patients were distributed across 10 international specialist neurochemical laboratories for analysis by a range of commercial and in-house neurofilament assays. The performance of all assays was evaluated for their ability to differentiate between the groups. The inter-assay coefficient of variation was calculated where appropriate from sample measurements performed across multiple laboratories using the same assay.

Results: All assays could differentiate ALS patients from controls in CSF. Inter-assay coefficient of variation of analytical platforms performed across multiple laboratories varied between 6.5% and 41.9%.

Conclusions: This study is encouraging for the growing momentum toward integration of neurofilament measurement into the specialized ALS clinic. It demonstrates the importance of 'round robin' studies necessary to ensure the analytical quality required for translation to the routine clinical setting. A standardized neurofilament probe is needed which can be used as international benchmark for analytical performance in ALS.

Introduction

Neurofilament light chain (NfL) and phosphorylated neurofilament heavy chain (pNfH) are among the most promising candidate neurochemical biomarkers in amyotrophic lateral sclerosis (ALS). In recent years, there has been a surge in studies describing their performance in the diagnostic phase and their utility as prognostic biomarkers [1-8]. Although these studies have consistently demonstrated the elevation of pNfH and NfL in the CSF and blood of ALS patients, the concentrations among studies varies considerably.

Studies have identified pre-analytical factors that may influence neurofilament determination and demonstrated that efforts focussed on the optimisation and standardisation of biofluid collection and processing have been successful [9, 10]. In order to implement neurofilament assays into routine clinical practice, it is important to independently assess and standardize the performance of the currently available assays across multiple platforms and laboratories. In this study, CSF and blood samples were sent from a single centre to 10 participating laboratories across Europe and the USA for the measurement of NfL and pNfH, investigating the consistency of differentiation between ALS and controls and inter-laboratory variation across assays.

Methods

Patients

Samples (five with ALS and five disease controls) were obtained from individuals attending the University of Ulm Department of Neurology Clinic (Ulm, Germany) with informed consent (ethical approval number 20/10). Patient characteristics are shown in Table 1. Disease controls had no neurodegenerative disease and CSF was collected to exclude a chronic neuroinflammatory process. Their final diagnoses were: myositis, adenoma of pituitary gland, polyneuropathy, SVE, vertigo.

Biofluid sample collection

CSF was obtained by lumbar puncture directly into polypropylene collection tubes. Venous blood was collected into serum separator tubes and EDTA tubes (for plasma extraction). Biofluid samples were centrifuged at 3000rpm for 10 minutes at 4°C within one hour of sampling and stored at -80°C. CSF, serum and plasma samples; one aliquot from each ALS (n=5) and control (n=5) patient were shipped on dry ice from the Department of Neurology, Ulm University Hospital to each participating centre: (Nuffield Department of Clinical Neuroscience, University of Oxford (UK); Department of Neurology, Ulm University Hospital (Germany); University of Gothenburg (Sweden); Pitié-Salpêtrière Hospital, Paris (France); University of Basel (Switzerland); Queen Mary University of London UK; University of Leuven (Belgium); VU Medical Centre, Amsterdam (Netherlands); University College London, Institute of Neurology (UK); Iron Horse Diagnostics, Inc., Scottsdale, AZ (USA). All samples were stored at -80°C until analysis.

Determination of pNfH and NfL in serum, plasma and CSF

The details of each assay platform used is outlined in Table 2. Each NfL was measured using four different assays in CSF (Simoa NF-light® assay, In-house Simoa NFL assay, IBL International NF-light® ELISA and an in-house ELISA method[11]); three different assays in serum (Simoa NF-light® assay, In-house Simoa NFL assay and an in-house NfL Meso Scale Discovery assay) and two different assays in plasma (Simoa NF-light® assay and an In-house Simoa NFL [12]). pNfH was measured using four different assays in CSF (Simoa pNF-Heavy, BioVendor, Euroimmun and an in-house pNfH Luminex assay [13]; four different assays in serum (Simoa, BioVendor,

Euroimmun and an in house MSD assay) and four different assays in plasma (Simoa, BioVendor, Euroimmun and an in house MSD assay). sample was assayed twice to generate two replicates on each platform. Any samples for which neurofilament levels were below the limit of detection (LOD) the LOD value was used in statistical analysis.

Statistics

Statistical analysis was performed using GraphPad Prism 7. The ALS and disease control groups were compared by the Mann-Whitney test ($p < 0.05$ significant).

Results

Assay performance in CSF

The CSF concentration of NfL was significantly increased in ALS patients compared with neurological controls when measured by four different analytical platforms in eight centres (Figure 1). The CSF concentration of pNfH was significantly increased in ALS patients compared with neurological controls as measured by five different analytical platforms in eight centres (Figure 2). In CSF, the frequency of endogenous analyte detection for all NfL assay platforms tested was 100%. For the measurement of CSF pNfH levels, undetectable values were encountered in 20% of samples assayed using the BioVendor platform.

Assay performance in blood

The serum concentration of NfL was significantly increased in ALS patients compared with neurological controls when measured by the Simoa platform (commercial and in-house) in five centres (Figure 3a). The plasma concentration of NfL was significantly increased in ALS patients compared to neurological controls when measured by the Simoa platform (commercial and in-house) in four centres (Figure 3b). The serum and plasma concentration of pNfH was significantly increased in ALS patients compared with neurological controls when measured by the Simoa platform in one centre (Figure 3c, d). In blood, the frequency of endogenous analyte detection was 100% for both NfL and pNfH using the Simoa platform. Serum and plasma pNfH and serum NfL were quantified using a total of 3 other analytical platforms, whereby 90% of the sample concentrations were above the analytical sensitivity.

Inter-assay reliability of analytical platforms

Four different analytical platforms were used across multiple centres. The inter-assay coefficients of variation (CVs) of measurements by the Simoa NfL (serum = 5, plasma = 3, CSF = 3 centres), Euroimmun pNfH (serum = 3, plasma = 2, CSF = 3 centres),

Uman NfL (CSF = 4 centres) and BioVendor pNfH (CSF = 3 centres) are summarised in Table 3.

Discussion

This study sought to assess the performance of multiple neurofilament analytical platforms in a ‘round-robin’ exercise across 10 international ALS centres. Our findings demonstrate that pNfH and NfL can be sensitively quantified by all of the analytical platforms applied to the CSF of ALS patients and neurological controls across the study. The CSF concentrations of both NfL and pNfH were all in the analytical range of these assays. In agreement with another study [14], the Simoa assay provided the most sensitive quantification of pNfH and NfL levels in blood with serum and plasma concentrations of all subjects detected across multiple laboratories. For the assays that failed to differentiate ALS from disease controls in blood, 10% of serum and plasma pNfH and NfL concentrations were outside the analytical range in serum and EDTA plasma. These findings extend upon previous observations of increased pNfH and NfL levels in the blood and CSF of ALS patients and demonstrate that this increase is consistent and reliably detected across multiple analytical approaches. However as we used samples with very clear diagnosis of ALS and very high NfL levels, NfL seems to be superior compared to pNfH for the diagnosis of ALS. As this was seen with standard ELISA and also with the digital ELISA this seems to be independent of the platform.

We consider the inter-assay variability across laboratories performing the same assay to be acceptable. For future harmonisation of neurofilament measurements in the ALS field, we recommend that a reference method, as well as reference materials, should be established for a better comparison of clinically relevant cut-off levels. The use of a quality control programme based on the principles highlighted by this study will ensure that all participating laboratories are aligned with other users of the assay.

Funding: HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (#2018-02532), the European Research Council (#681712), Swedish State Support for Clinical Research (#ALFGBG-720931), the Leonard Wolfson

Experimental Neurology Centre, and the UK Dementia Research Institute at UCL. A Wellcome Trust Multi-User Equipment Grant to AH and HZ supported the purchase of the Simoa instrument at UCL.

Conflicts of interest: HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg (all outside submitted work).

References

1. Benatar, M., et al., *Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion*. *Ann Neurol*, 2018. **84**(1): p. 130-139.
2. De Schaepdryver, M., et al., *Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis*. *J Neurol Neurosurg Psychiatry*, 2018. **89**(4): p. 367-373.
3. Feneberg, E., et al., *Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis*. *Neurology*, 2018. **90**(1): p. e22-e30.
4. Gendron, T.F., et al., *Phosphorylated neurofilament heavy chain: A biomarker of survival for C9ORF72-associated amyotrophic lateral sclerosis*. *Ann Neurol*, 2017. **82**(1): p. 139-146.
5. Lu, C.H., et al., *Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis*. *Neurology*, 2015. **84**(22): p. 2247-57.
6. Poesen, K., et al., *Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease*. *Neurology*, 2017. **88**(24): p. 2302-2309.
7. Verde, F., et al., *Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis*. *J Neurol Neurosurg Psychiatry*, 2019. **90**(2): p. 157-164.
8. Weydt, P., et al., *Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis*. *Ann Neurol*, 2016. **79**(1): p. 152-8.
9. Lehnert, S., et al., *Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis*. *Amyotroph Lateral Scler Frontotemporal Degener*, 2014. **15**(5-6): p. 344-50.
10. Oeckl, P., et al., *Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS*. *Amyotroph Lateral Scler Frontotemporal Degener*, 2016. **17**(5-6): p. 404-13.

11. Gaetani, L., et al., *A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation*. *Alzheimers Res Ther*, 2018. **10**(1): p. 8.
12. Steinacker, P., et al., *Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease*. *Sci Rep*, 2016. **6**: p. 38737.
13. Koel-Simmelink, M.J., et al., *The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA*. *J Immunol Methods*, 2014. **402**(1-2): p. 43-9.
14. Wilke, C., et al., *Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches*. *Clin Chem Lab Med*, 2019. **57**(10): p. 1556-1564.

Figure Legends

Figure 1: Detection of neurofilament light chain (NfL) in the cerebrospinal fluid (CSF) of ALS patients and neurological controls. Scatter dot plots show neurofilament light chain concentrations in the CSF of patients with ALS and neurological controls. Filled circles, black - Lab 1 In-house Simoa assay; Filled circles, cyan – Lab 1 Simoa assay; Filled squares, cyan – Lab 2 Simoa assay; Filled inverted triangles, Lab 4 Simoa assay; Filled triangles, green – Lab 3 Uman ELISA; Empty circles, green – Lab 6 Uman ELISA; Empty triangles, green – Lab 8 Uman ELISA; Empty diamond, green – Lab 10 Uman ELISA; Filled hexagon, purple; Lab 7 – In-house ELISA. Median value and interquartile range are shown. Mann-Whitney U test was used for the comparisons. ** $p < 0.01$

Figure 2: Detection of phosphorylated neurofilament heavy chain (pNfH) in the cerebrospinal fluid (CSF) of ALS patients and neurological controls. Scatter dot plots show phosphorylated neurofilament heavy chain concentrations in the CSF of patients with ALS and neurological controls. Empty inverted triangles, blue – Lab 9 In-house MesoScale Discovery assay; Filled squares, cyan – Lab 2 Simoa assay; Filled squares, magenta – Lab 2 BioVendor ELISA; Filled triangles, magenta – Lab 3 BioVendor ELISA; Empty diamonds, magenta – Lab 10 BioVendor ELISA; Filled diamonds, yellow – Lab 5 Euroimmun ELISA; Empty inverted triangles, yellow – Lab

9 Euroimmun ELISA; Empty triangles, yellow – Lab 8 Euroimmun ELISA; Inverted triangles, red – Lab 4 Luminex Assay. Median value and interquartile range are shown. Mann-Whitney U test was used for the comparisons. ** $p < 0.01$

Figure 3: Detection of neurofilament light chain (NfL) and phosphorylated neurofilament heavy chain (pNfH) by the Simoa platform in the serum and plasma of ALS patients and neurological controls. Scatter dot plots show **A** neurofilament light chain concentrations in the serum of patients with ALS and neurological controls; Filled circles, black; In-house Simoa assay Lab 1 **B** neurofilament light chain concentrations in the plasma of patients with ALS and neurological controls; Filled circles, black; In-house Simoa assay Lab 1; Filled hexagons, black; In-house Simoa assay Lab 7 **C** phosphorylated neurofilament heavy chain concentrations in the serum of patients with ALS and neurological controls; **D** phosphorylated neurofilament heavy chain concentrations in the plasma of patients with ALS and neurological controls. Median value and interquartile range are shown. Mann-Whitney U test was used for the comparisons. ** $p < 0.01$

